Stock Market: Will S&P 500 Open Up or Down Today?
Will S&P 500 open higher? Polymarket odds sit at 52% as Wall Street weighs 5.35% Treasury yields, potential Iran strikes, and Pepsi earnings.
Stocks · News reference
Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38
Morgan Stanley analyst Terence Flynn maintains Nurix Therapeutics (NASDAQ:NRIX) with a Overweight and raises the price target from $36 to $38.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration
First patient enrolled in cohort combining bexobrutideg with venetoclaxInitial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLLStrategy includes evaluation of bexobrutideg given in
Nurix Gets $10M As Gilead Extends Drug Discovery Deal
Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and
Nurix Therapeutics Announces $7M Research Milestone Payment From Pfizer Under Degrader Antibody Conjugate Collaboration